NASDAQ:NTEC - Intec Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.36 +0.22 (+4.28 %) (As of 05/24/2019 03:19 PM ET)Previous Close$5.14Today's Range$5.21 - $5.4152-Week Range$3.55 - $9.25Volume3,108 shsAverage Volume256,521 shsMarket Capitalization$175.95 millionP/E RatioN/ADividend YieldN/ABeta0.29 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel. Receive NTEC News and Ratings via Email Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTEC Previous Symbol CUSIPN/A CIK1638381 Webhttp://www.intecpharma.com/ Phone972-2586-4657Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book4.00Profitability EPS (Most Recent Fiscal Year)($1.40) Net Income$-43,540,000.00 Net MarginsN/A Return on Equity-73.47% Return on Assets-63.78%Miscellaneous Employees70 Outstanding Shares32,826,000Market Cap$175.95 million Next Earnings Date8/21/2019 (Estimated) OptionableOptionable Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions What is Intec Pharma's stock symbol? Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC." How were Intec Pharma's earnings last quarter? Intec Pharma Ltd (NASDAQ:NTEC) posted its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. View Intec Pharma's Earnings History. When is Intec Pharma's next earnings date? Intec Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, August 21st 2019. View Earnings Estimates for Intec Pharma. What price target have analysts set for NTEC? 5 Wall Street analysts have issued 1 year price targets for Intec Pharma's shares. Their forecasts range from $8.50 to $16.00. On average, they expect Intec Pharma's share price to reach $13.30 in the next year. This suggests a possible upside of 148.1% from the stock's current price. View Analyst Price Targets for Intec Pharma. What is the consensus analysts' recommendation for Intec Pharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intec Pharma. What are Wall Street analysts saying about Intec Pharma stock? Here are some recent quotes from research analysts about Intec Pharma stock: 1. LADENBURG THALM/SH SH analysts commented, "We know the AP-cannabis compounds are so oily they require a reservoir, which is unlike the two immediate-release (IR) and one extended-release (XR) films in AP-CD/LD. So again, the films are specific to the API. Management has described AP’s technology as uniquely suited to low soluble drugs, but we do not know if that describes either of the two major pharma’s proprietary drugs." (5/16/2019) 2. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (5/7/2019) 3. Maxim Group analysts commented, "Intec announced positive data from the PK study in Parkinson’s disease (PD) patients (N=12) of Accordion Pill Carbidopa/Levodopa (AP – CD/LD) demonstrating significantly reduced plasma levodopa variability as measured by levodopa fluctuation index (P<0.005). The data is reviewed below."" (2/19/2019) Has Intec Pharma been receiving favorable news coverage? News stories about NTEC stock have been trending negative on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intec Pharma earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Intec Pharma's key competitors? Some companies that are related to Intec Pharma include Aptorum Group (APM), ChemoCentryx (CCXI), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), Stemline Therapeutics (STML), Organogenesis (ORGO), Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Crinetics Pharmaceuticals (CRNX), CannTrust (CTST), Akebia Therapeutics (AKBA), Lexicon Pharmaceuticals (LXRX) and Aurinia Pharmaceuticals (AUPH). What other stocks do shareholders of Intec Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include Viking Therapeutics (VKTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Global Blood Therapeutics (GBT), NVIDIA (NVDA), Zynerba Pharmaceuticals (ZYNE), Catalyst Pharmaceuticals (CPRX), Sangamo Therapeutics (SGMO) and BioDelivery Sciences International (BDSI). Who are Intec Pharma's key executives? Intec Pharma's management team includes the folowing people: Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 52)Mr. Nir Sassi, Chief Financial Officer (Age 43)Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 50)Mr. Walt Addison Linscott, Chief Bus. Officer (Age 58)Dr. R. Michael Gendreau, Chief Medical Officer (Age 63) When did Intec Pharma IPO? (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO. Who are Intec Pharma's major shareholders? Intec Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Meitav Dash Investments Ltd. (8.39%), Prosight Management LP (1.65%), Essex Investment Management Co. LLC (1.13%), Knott David M (0.88%), Morgan Stanley (0.18%) and ARK Investment Management LLC (0.17%). Which major investors are selling Intec Pharma stock? NTEC stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Prosight Management LP, ARK Investment Management LLC, Meitav Dash Investments Ltd. and Essex Investment Management Co. LLC. Which major investors are buying Intec Pharma stock? NTEC stock was purchased by a variety of institutional investors in the last quarter, including Menta Capital LLC, Private Advisors LLC, Morgan Stanley, Sigma Planning Corp, Dimensional Fund Advisors LP, Delek Group Ltd., Marshall Wace North America L.P. and Knott David M. How do I buy shares of Intec Pharma? Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intec Pharma's stock price today? One share of NTEC stock can currently be purchased for approximately $5.36. How big of a company is Intec Pharma? Intec Pharma has a market capitalization of $175.95 million. The biotechnology company earns $-43,540,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Intec Pharma employs 70 workers across the globe. What is Intec Pharma's official website? The official website for Intec Pharma is http://www.intecpharma.com/. How can I contact Intec Pharma? Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected] MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 434MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Dividend Yield Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.